UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised 9,500 stock options and sold the resulting 9,500 shares of UTHR common stock for about $5 million under a 10b5‑1 plan on July 30, 2026.

On July 30, 2026, United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options with a $135.42 strike price, acquiring an equal number of United Therapeutics common shares, and concurrently sold all 9,500 resulting shares in multiple open‑market transactions under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. The sales were executed in several tranches at weighted average prices between approximately $523.04 and $528.96 per share, generating proceeds of roughly $4.99 million while the option exercise cost about $1.29 million, implying a spread of around $3.7 million. After these transactions, the reporting person continued to hold substantial indirect beneficial ownership through various family trusts and a spouse’s holdings, including 324,443 shares in the primary trust reported in these trades and additional common stock positions and stock options in other family trusts detailed in the filing. The activity appears to be part of a larger, ongoing program to systematically exercise up to 1,734,410 options expiring March 15, 2027, or until December 31, 2026, rather than a discretionary one‑off trade.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000110

Alert Tier

7